Posted by Michael Wonder on 26 Aug 2025
Rusfertide receives breakthrough therapy designation for treatment of erythrocytosis in patients with polycythemia vera
25 August 2025 - Breakthrough therapy designation complements rusfertide's orphan drug and fast track designations, which together confer multiple benefits to the development program.
Protagonist Therapeutics announced today that rusfertide, a potential first in class hepcidin mimetic peptide, has been granted breakthrough therapy designation by the US FDA for the treatment of erythrocytosis in patients with polycythemia vera.
